Clinical Significance of a Point Mutation in DNA Polymerase Beta (POLB) Gene in Gastric Cancer

Abstract

Gastric cancer (GC) is a major cause of global cancer mortality. Genetic variations in DNA repair genes can modulate DNA repair capability and, consequently, have been associated with risk of developing cancer. We have previously identified a T to C point mutation at nucleotide 889 (T889C) in DNA polymerase beta (POLB) gene, a key enzyme involved in base excision repair in primary GCs. The purpose of this study was to evaluate the mutation and expression of POLB in a larger cohort and to identify possible prognostic roles of the POLB alterations in GC. Primary GC specimens and their matched normal adjacent tissues were collected at the time of surgery. DNA, RNA and protein samples were isolated from GC specimens and cell lines. Mutations were detected by PCR-RFLP/DHPLC and sequencing analysis. POLB gene expression was examined by RT-PCR, tissue microarray, Western blotting and immunofluorescence assays. The function of the mutation was evaluated by chemosensitivity, MTT, Transwell matrigel invasion and host cell reactivation assays. The T889C mutation was detected in 18 (10.17%) of 177 GC patients. And the T889C mutation was associated with POLB overexpression, lymph nodes metastases and poor tumor differentiation. In addition, patients with- the mutation had significantly shorter survival time than those without-, following postoperative chemotherapy. Furthermore, cell lines with T889C mutation in POLB gene were more resistant to the treatment of 5-fluorouracil, cisplatin and epirubicin than those with wild type POLB. Forced expression of POLB gene with T889C mutation resulted in enhanced cell proliferation, invasion and resistance to anticancer drugs, along with increased DNA repair capability. These results suggest that POLB gene with T889C mutation in surgically resected primary gastric tissues may be clinically useful for predicting responsiveness to chemotherapy in patients with GC. The POLB gene alteration may serve as a prognostic biomarker for GC.

WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance

“…These data suggest that the levels of ATR, CHK1, especially WEE1, modulate cisplatin mediated cell death and survival, which is also reflected by our analysis of clinic data on ovarian cancer patients and breast cancer patients undergone chemotherapy, which contains cisplatin. Because cisplatin resistance frequently occurs123456789101112, our finding should have a significant impact in clinic applications in combating with cisplatin resistant cancers. As several other platinum-based drugs, such as carboplatin, are also used in treating various cancers, we will study their synergy with WEE1i in combating with breast cancer in near future.…”

Systems Biology Approaches for the Prediction of Possible Role of Chlamydia pneumoniae Proteins in the Etiology of Lung Cancer

“…A frequently stated assumption is that anomalies in translesion DNA synthesis or error-prone phenotypes in DNA replication participate in genomic DNA instability and are prominent cause of the development of cancer. Such, erroneous DNA replication mechanisms have been implicated as an etiological factor in many cancers [ 33 – 35 ].…”

“…For instance, DNA polymerase beta protein is involved in approximate 30% all human tumors reported to date due to mutations [ 33 , 34 ]. The bacterial DNA polymerase III subunit beta has a homolog of eukaryotic proliferating cell nuclear antigen (PCNA).…”

MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer

“…A point mutation, or single base modification, is a type of mutation that causes a single nucleotide base substitution, insertion or deletion of genetic material. Point mutations have been proven to influence expression of many genes (17)(18)(19). In addition, miRNA gene point mutations have been reported in almost all types of cancer (20,21).…”